Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia
The DOI matches its Crossref record.
Abstract
UNLABELLED: Prenatal treatment of virilizing congenital adrenal hyperplasia in female fetuses via maternal dexamethasone (Dex) therapy (1-1.5 mg/day) from first trimester to birth was associated with excessive weight gain (47-56 pounds at 35-37 weeks gestation), Cushingoid facial features, severe striae resulting in permanent scarring, and hyperglycemic response (8-11.7 nmol/L) to oral glucose administration in all our experience (three cases). Other symptoms included hypertension, gastrointestinal intolerance, or extreme irritability. Previous pregnancies were uncomplicated by these problems. In each case, first or second trimester amniotic fluid 17-hydroxyprogesterone (17OHP, 17-41 nmol/L; normal less than 0.4 nmol/L), androstenedione (22-31 nmol/L, normal less than 5 nmol/L), and testosterone levels (0.54-0.7 nmol/L, normal less than 0.4 nmol/L) during Dex treatment were elevated regardless of the newborn genital outcome. Maternal serum estriol (E3) levels in one mother (normal newborn genitalia) were consistently low (less than 0.2 nmol/L) during the second and third trimester. In two mothers (partially virilized newborn genitalia) initial second trimester E3 levels were unsuppressed (11, 17.4 nmol/L) and suppressed (less than 1.4 nmol/L) following short-term increased dose. CONCLUSION: prenatal Dex treatment of virilizing congenital adrenal hyperplasia at a dose of 1-1.5 mg daily throughout gestation is associated with significant maternal side effects. Parents should be informed of these side effects before initiation of treatment. Careful monitoring for signs of side effects, medical intervention when necessary, and lowering of Dex dose during the second half of gestation would minimize the side effects. Maternal serum E3 levels appear useful for prediction of fetal outcome while amniotic fluid steroid levels may not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency*
White, P. C., & Speiser, P. W. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.3.0398 · Cited by 1,432
“This implies a disease frequency for nonclassic 21-hydroxylase deficiency of 0.06%, in good agreement with estimates in the general American population (195).”
BackgroundInfluentialCongenital Adrenal Hyperplasia
(1987) · New England Journal of Medicine · doi:10.1056/nejm198711263172211 · Cited by 1,409
Congenital adrenal hyperplasia
Speiser, P. W., & White, P. C. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021561 · Cited by 1,405
Congenital adrenal hyperplasia.
Merke, D. P., & Bornstein, S. R. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66736-0 · Cited by 628
van der Woude, C. J., Ardizzone, S., Bengtson, M. B., Fiorino, G., Fraser, G., Katsanos, K., Kolacek, S., Juillerat, P., Mulders, A. G. M. G. J., Pedersen, N., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jju006 · Cited by 475
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Seckl, J. R. (1997) · Steroids · doi:10.1016/s0039-128x(96)00165-1 · Cited by 298
European Crohn’s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation
Torres, J., Chaparro, M., Julsgaard, M., Katsanos, K., Zelinkova, Z., Agrawal, M., Ardizzone, S., Campmans-Kuijpers, M., Dragoni, G., Ferrante, M., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac115 · Cited by 281
Raff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141
“As a result, the strategy is controversial and a recent guideline suggested that this be provided only within the context of an IRB-reviewed clinical trial (163,167,190,238).”
How safe is long-term prenatal glucocorticoid treatment?
Seckl, J. R. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540370067039 · Cited by 118
Prenatal treatment of congenital adrenal hyperplasia
Lajic, S., Nordenstrom, A., Ritzen, E., & Wedell, A. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.151u063 · Cited by 67
Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia
Nimkarn, S., Lin-Su, K., & New, M. I. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2009.08.001 · Cited by 52
Prenatal treatment of congenital adrenal hyperplasia-not standard of care
Witchel, S. F., & Miller, W. L. (2012) · Journal of Genetic Counseling · doi:10.1007/s10897-012-9508-8 · Cited by 29
“Other studies have reported Cushingoid effects in small numbers of treated women (Pang et al. 1992).”
BackgroundGorduza, D., Tardy-Guidollet, V., Robert, E., Gay, C.-L., Chatelain, P., David, M., Bretones, P., Lienhardt-Roussie, A., Brac de la Perriere, A., Morel, Y., et al. (2014) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2014.02.003 · Cited by 20
Metadata
- Authors
- Pang, S.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1992-07-01
- Volume
- 75
- Issue
- 1
- Pages
- 249-253
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2113376917
- Cited by
- 92
- References
- 0
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.